Fred Alger Management LLC Has $1.40 Million Holdings in Health Catalyst, Inc. $HCAT

Fred Alger Management LLC decreased its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 17.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 308,541 shares of the company’s stock after selling 64,324 shares during the period. Fred Alger Management LLC owned approximately 0.44% of Health Catalyst worth $1,398,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of HCAT. Group One Trading LLC lifted its stake in shares of Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after purchasing an additional 2,260 shares during the period. XTX Topco Ltd bought a new stake in Health Catalyst in the first quarter worth approximately $54,000. Brevan Howard Capital Management LP acquired a new position in Health Catalyst in the fourth quarter valued at approximately $92,000. ProShare Advisors LLC lifted its stake in Health Catalyst by 52.7% in the fourth quarter. ProShare Advisors LLC now owns 16,854 shares of the company’s stock valued at $119,000 after buying an additional 5,815 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of Health Catalyst during the 1st quarter worth approximately $113,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently issued reports on HCAT. Canaccord Genuity Group dropped their target price on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 29th. Evercore ISI lifted their price target on shares of Health Catalyst from $3.00 to $4.00 and gave the company an “in-line” rating in a research note on Thursday, August 28th. BTIG Research reissued a “neutral” rating on shares of Health Catalyst in a research report on Friday, September 5th. Summit Redstone set a $5.00 target price on Health Catalyst in a research note on Friday, August 29th. Finally, Wells Fargo & Company dropped their price target on Health Catalyst from $10.00 to $6.00 and set an “overweight” rating on the stock in a research note on Monday, August 11th. Three analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $4.73.

Health Catalyst Price Performance

HCAT stock opened at $3.40 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. The business has a 50-day simple moving average of $3.56 and a two-hundred day simple moving average of $3.90. The company has a market capitalization of $239.27 million, a P/E ratio of -2.25 and a beta of 1.53. Health Catalyst, Inc. has a 52-week low of $2.52 and a 52-week high of $9.24.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.